Log In
BCIQ
Print this Print this
 

HER2.taNK

  Manage Alerts
Collapse Summary General Information
Company NantKwest Inc.
DescriptionStable clonal HER2-specific NK-92 cell line
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat HER2 positive breast cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today